title: [Biological therapies in rheumatology].
abstract: Biological therapies consisting of monoclonal antibodies and soluble receptors have revolutionized the care of rheumatologic patients. These therapies ensued from a better understanding of the physiopathology of rheumatologic disorders. Most of the latter have been concerned: rheumatoid arthritis (for about 10 years), psoriatic arthritis and ankylosing spondilitys (for more or less five years). Rheumatology was among the first disciplines to make use of these advances; it continues to benefit from the results of intense research efforts. These developments request from clinicians an increased expertise in immunology.
authors: Service de Rhumatologie, CHU de Liège, Belgique.
authors: C
authors: C
authors: Von Frenckell
authors: M G
authors: MG
authors: Malaise
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001168:Arthritis / Q000188:drug therapy*; D000068582:Certolizumab Pegol; D000068800:Etanercept; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D011092:Polyethylene Glycols / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept; D000068582:Certolizumab Pegol